# First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years

> **NCT03492775** · PHASE2 · COMPLETED · sponsor: **Prof. Dr. Wolfgang Hiddemann** · enrollment: 46 (actual)

## Conditions studied

- Indolent Non-hodgkin Lymphoma

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT03492775
- **Lead sponsor:** Prof. Dr. Wolfgang Hiddemann
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-12
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-03-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03492775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03492775, "First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03492775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*